StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) Reports Initiation of New Global Clinical Trial, DEVOTE, Evaluating Higher Dose of SPINRAZA (nusinersen) & Additional Data
September 18, 2019 7:34 AM
Biogen Inc. (NASDAQ: BIIB) today announced updates to the SPINRAZA (nusinersen) clinical development program including the initiation of a new ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
September 18, 2019 7:30 AM
Biogen (BIIB) BG00011 Just Stopped For Toxicity, But Low Impact - RBC
September 16, 2019 1:51 PM
S&P 500 Q2 Stock Buybacks Fall 20.1% Sequentially, 13.7% YoY
September 16, 2019 11:34 AM